A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT02789358
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 140 participants
- Registry
-
NCT02789358
-
- Other papers using this trial's data
- Time-to-Effect-Based Dosing Strategy for Cryoballoon Ablation in Patients With Paroxysmal Atrial Fibrillation: Results of the plusONE Multicenter Randomized Controlled Noninferiority Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Spain
- Registry status
- Completed
Technical summary
Registry record NCT02789358. Randomized; single masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation
- Acronym
- plusONE
- Condition
- Atrial Fibrillation
- Intervention (Other)
- Conventional cryotherapy dosage
- Intervention (Other)
- Experimental cryotherapy dosage
- Intervention (Device)
- Arctic Front Advance ST Cryoenergy Balloon Catheter
- Intervention (Drug)
- Adenosine triphosphate
- Intervention (Device)
- nECG platform Nuubo®
- Lead sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Record details
- Record id
cardio:ct-nct02789358- Content hash
9c5bb22e468e8a4970ea5370ba2064be15715db97975c50cc452766bc759c667